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Shift from Acute to Chronic Disease Management










Source:  National Hospital Discharge Survey, CDC/NCHS and NHLBI.
Worse 5 year survival rate than any cancer except lung cancer
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Heart Failure: Nature of Problem
The cost of failure by Hal A. Skopicki, MD, August 2007
“What about the long-term mortality ramifications of actions taken during the acute hospitalization? Although 
more than 90% of heart failure patients are hospitalized with volume overload, less than 50% lose more than 
5 pounds during the acute hospitalization.
8
This may reflect the difficulty in clinically assessing persistent 
volume overload
9
or the fear of inducing renal dysfunction in a patient population where renal function 
predicts not only in-hospital but also long-term mortality”.
10-14
“It is therefore surprising that no 
technologically pragmatic application exists to 
guide the aggressiveness of diuresis or to 
gauge when euvolemia has been established.”
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Heart FailureBlood Glucose Diabetes
D R I V E S
In the same way that… We know that…
Intracardiac Pressure
D R I V E S
Proactively managing cardiovascular pressure is critical to chronic management of HF
How to Reduce HF Hospitalizations?
Study Design: 
Monitoring Can Reduce Hospitalizations
p(a) % DeclineMeasure
Medtronic COMPASS Trial: 274 pts, Class 3 & 4
Reduction in the rate of HF events  21%p=0.33
Reduction in the proportion of 
patients with worsening heart failure  36%p=0.035
Reduction in heart failure event: 
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Pressure in heart increases before adverse events
Source: Journal of the American College of Cardiology, Adamson PB et al. J Am Coll Cardiol.2003; 41: 565.
(a) p values less than 0.05 are considered statistically significant.
7
8





Goal of Endovascular Repair:
Reduce Pressure and Wall Strain to Prevent 
Rupture
Long Term Monitoring Challenge::
Potential for Re-Pressurization via Leaks: 
Monitored by Contrast Tomography (CT)








• Jay Yadav, M.D. 
• CEO and Chairman of the Board, CardioMEMS Inc
• Interventional Cardiologist, Piedmont Hospital
• Founder and Chairman of AngioGuard, Inc. (sold to J&J in 1998)
• Mark Allen, Ph.D.
– Chief Technology Officer, CardioMEMS Inc.
– Senior Vice Provost for Research and Innovation; Joseph M. Pettit Professor; 
Regents Professor, Georgia Institute of Technology.
Co-founder, Redeon (acquired by BioValve in 2001)
–Licensed Core IP from Georgia Tech and MIT
CardioMEMS Founders
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CardioMEMS at a Glance
• Founded 2001
• Approximately 65 employees
• Aortic Aneurysm Sensor 
– FDA 510k Clearance
– Over 7,000 sold & implanted
• Heart Failure Sensor
– 550 Patient Pivotal Clinical Study Completed – Results Pending
– > 600 implanted in clinical studies worldwide.
• Only approved, permanently implanted wireless sensor






























Electromagnetic Vibration of the Sensor Circuit is based on 
Electrical Characteristics
Analogous Concept:
Mechanical Vibration of a Tuning Fork is Based on  
Mechanical Characteristics
Sensor Frequency to Pressure Translation
Measurement of Pressure
is Based on
Frequency of Electromagnetic 
Resonant Circuit
Equivalent Circuit
Passive Wireless Pressure: 
Appealing Concept
Further Learning and Innovation Required:
• Long Term Stability – Material and Process Selection
• Detection Distance – RF Innovation and Chipset Advancements
• Miniaturization for Minimally Invasive Implant – MEMS





























Sensor Attributes and Features
• No Internal Power Supply






Nano Scale Sensor Features
Pressure Sensitive MEMS Capacitor:
Design:
~ 1 μm Capacitor Air Gap
~ 1 nm Deflection / mm Hg
Across 6” Wafer:
+/- 12nm Electrode Height Uniformity
+/- 100nm Trench Depth
Materials:
Dimensional Stability for Baseline within +/-2 mmHg/year = 
+/- ~2nm/year
Electromagnetic Vibration of the Sensor Circuit is based on 
Electrical Characteristics
Analogous Concept:
Mechanical Vibration of a Tuning Fork is Based on  
Mechanical Characteristics
Sensor Frequency to Pressure Translation
Measurement of Pressure
is Based on





A 2us burst of RF is sent to the 
sensor via magnetic “loosely 
coupled transformer” coupling.
During the excitation 
burst, the sensor reacts 
at the same frequency 
as it gathers energy.
When the excitation is removed, the 
sensor “free-wheels” at its natural 






EndoSure™ Sensor Launch Training
Theory of Operation
• Sensor signal decays completely within 2 μs
• Transmit / Receive Power
– Transmit: ~0.9 W
– Receive: ~100pW (1 billionth of a Watt)
• Sensor signal sample must be collected within 35 ns of 
transmit burst, due to rapid decay.
• Sampling rate: 100kHz
Heart Failure Implant and Use Animation
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Introduction: Pulmonary Artery Anatomy
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Pulmonary Artery Implant Site:
• PA pressure – key parameter of cardiac 
function.
• PA placement – lower risk profile than 
alternate implant sites.
– Right side – no stroke risk
– No active fixation required





Target Implant Site Characteristics
• Right or left PA branch, basal 
(lower) lobe, descending branch, 
pre-bifurcation
• Within 4” of side and back
• Vessel Lumen ID approx. 7-15mm
• Aligned with long axis of body

















Sensor Does Not Impact Blood Flow
Sensor in Distal PA
Histopathology Results
• Histopathology shows that the sensor body was covered with mature and stable fibrous 
pseudointima 
• Sensor loops were covered with mature stable neointima
• No evidence of foreign body response or thrombosis
• Confirms positive human safety profile and histopathology results of animal studies
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Ohio State University - Dr. William Abraham
Case Study Subject
52 yo White Male                                                                   CM Sensor Implant 1/30/08
Baseline Medications
Carvedilol  37.5mg BID Digoxin 0.125mg QD
Lisinopril  10mg QD Aspirin 81mg QD
Eplerenone 25mg QD Coumadin as directed
Bumetanide 1mg BID KCL 10 meq BID
Amiodarone 200mg BID
Swan at Implant:
PA 51/24(36)  PCWP 16  CO 5.1 PVR 3.92
Baseline Vitals:
BP 127/75  HR 75  WGT 176 lbs.  BMI 26
Baseline Labs:
SCr 1.2  GFR 68
Medical History
•Familial Dilated Cardiomyopathy
•ICD with CRT •Gout
•HTN •Depression




Start Torsemide 40mg BID 
↑Lisinopril 10mg am, 15mg pm Repeat RHC:
Sensor 27/15(19) 













CO and TPR Estimated from Pressure Waveform
Note high 
TPR values 







PA Hemodynamic Trends Example
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• 75 US sites, 550 patients, NYHA Class III with 90% statistical power 
• Primary Endpoint
– Rate of heart failure hospitalizations within six months
• Secondary Endpoints
– Percent of change in pulmonary artery pressure from baseline 
– Proportion of subjects hospitalized
– Number of days alive outside of hospital
– Total Quality of Life Measure from the Minnesota Heart Failure
• Additional Endpoint – Cost Effectiveness Substudy
• Timing
– PMA filing expected in 2Q 2010, FDA Approval expected in 4Q 
2010
CHAMPION US Pivotal Study Design
Heart Failure Multi Center Randomized Controlled Study 
World Wide HF Patient Enrollment: 
Pivotal Trial Enrollment Completed
• First Patient Implanted: December 16, 2005
• Latest Patient Implanted: October 7, 2009
• Total Patients Implanted World Wide: 602
– South America Feasibility: 27; Germany Feasibility: 8; US Feasibility: 
17
– US Pivotal: 550 of 550
• World Wide Patient Days:
– Total: 218,942.  Mean: 365 250 days.  Max: 1336 days
• Procedure Time: ~ 30 min
– Sensor Implant: ~ 7 min
• 99% technical success with implant
• ~ 94% patient compliance
• Upcoming Presentation on Trial at ESC Meeting in Berlin on May 31, 2010
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No UADEs Related to System
Conclusions
Successful Implementation of Nanotech Attributed to:
• Technology Development was Driven by Unmet 
Medical Needs
• Technical Needs were Uniquely Satisfied by MEMS 
Capabilities
• Design Philosophy
• Multidisciplinary R&D Approach
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